269 related articles for article (PubMed ID: 31307978)
1. Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects.
O'Donnell J; Preston RA; Mamikonyan G; Stone E; Isaacs R
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31307978
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment.
Bruss JB; Bader J; Hamed KA
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0050523. PubMed ID: 37823647
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis.
Sagan O; Yakubsevitch R; Yanev K; Fomkin R; Stone E; Hines D; O'Donnell J; Miller A; Isaacs R; Srinivasan S
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843995
[TBL] [Abstract][Full Text] [Related]
5. Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant
August B; Matlob A; Kale-Pradhan PB
Ann Pharmacother; 2024 Jul; 58(7):735-741. PubMed ID: 37817550
[TBL] [Abstract][Full Text] [Related]
6. Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects.
Rodvold KA; Gotfried MH; Isaacs RD; O'Donnell JP; Stone E
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126953
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function.
Berg JK; Tzanis E; Garrity-Ryan L; Bai S; Chitra S; Manley A; Villano S
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158281
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects.
O'Donnell J; Maloney K; Steidler M; Morrison R; Isaacs R
Clin Transl Sci; 2021 Jul; 14(4):1423-1430. PubMed ID: 33934519
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS; Shorr AF; Wunderink RG; Du B; Poirier GE; Rana K; Miller A; Lewis D; O'Donnell J; Chen L; Reinhart H; Srinivasan S; Isaacs R; Altarac D
Lancet Infect Dis; 2023 Sep; 23(9):1072-1084. PubMed ID: 37182534
[TBL] [Abstract][Full Text] [Related]
10.
O'Donnell J; Tanudra A; Chen A; Miller AA; McLeod SM; Tommasi R
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0031223. PubMed ID: 38092676
[TBL] [Abstract][Full Text] [Related]
11.
O'Donnell J; Tanudra A; Chen A; Newman J; McLeod SM; Tommasi R
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0080023. PubMed ID: 38092671
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Gepotidacin in Renal Impairment.
Hossain M; Tiffany C; Raychaudhuri A; Nguyen D; Tai G; Alcorn H; Preston RA; Marbury T; Dumont E
Clin Pharmacol Drug Dev; 2020 Jul; 9(5):560-572. PubMed ID: 32429000
[TBL] [Abstract][Full Text] [Related]
13. Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment.
Katsube T; Echols R; Arjona Ferreira JC; Krenz HK; Berg JK; Galloway C
J Clin Pharmacol; 2017 May; 57(5):584-591. PubMed ID: 27874971
[TBL] [Abstract][Full Text] [Related]
14. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
[TBL] [Abstract][Full Text] [Related]
15.
McLeod SM; Moussa SH; Hackel MA; Miller AA
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988095
[No Abstract] [Full Text] [Related]
16. Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment.
Preston RA; Mamikonyan G; DeGraff S; Chiou J; Kemper CJ; Xu A; Mastim M; Yeole R; Chavan R; Patel A; Friedland HD; Bhatia A
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397067
[TBL] [Abstract][Full Text] [Related]
17. Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of
Moussa SH; Shapiro AB; McLeod SM; Iyer R; Carter NM; Tsai Y-K; Siu LK; Miller AA
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0066523. PubMed ID: 37843305
[No Abstract] [Full Text] [Related]
18. The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex.
O'Donnell JP; Bhavnani SM
Clin Infect Dis; 2023 May; 76(Suppl 2):S202-S209. PubMed ID: 37125469
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment.
Patel G; Rodvold KA; Gupta VK; Bruss J; Gasink L; Bajraktari F; Lei Y; Jain A; Srivastava P; Talley AK
Antimicrob Agents Chemother; 2022 May; 66(5):e0240721. PubMed ID: 35420493
[TBL] [Abstract][Full Text] [Related]
20. Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.
Lobo ED; Heathman M; Kuan HY; Reddy S; O'Brien L; Gonzales C; Skinner M; Knadler MP
Clin Pharmacokinet; 2010 May; 49(5):311-21. PubMed ID: 20384393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
